Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A2102 +/- Adebrelimab in Advanced Breast Cancer
NCT07041437Phase 2Not yet recruiting
- Sponsor
- Fudan University
- Start
- Jun 2025
- Primary completion
- Sep 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of SHR-A2102 in breast cancer (2 arms), sponsored by Fudan University. Primary endpoint: Objective Response Rate. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
SHR-A2102
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07041437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07041437.